Background Information Metastatic castration-resistant prostate cancer (mCRPC) is a form of prostate cancer that keeps growing even when male hormones like testosterone are decreased to very low levels. Current treatments include drugs that block these hormones, chemotherapy, and hormone therapies. However, these treatments can stop working overtime. This clinical trial aims to test the safety and effectiveness of an investigational drug called MK-5684 to see if it may help stop or slow the spread of prostate cancer, specifically mCRPC. The study will look at how well MK-5684 may work...
Merck Patient Summaries
Omaha-004 Patient Summary – Metastatic Castration Resistant
This clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and whose cancer progressed on or after they were previously treated with next-generation Hormonal Agent (NHA). Study of Investigational Drug, MK5684, in Participants with Metastatic Castration-Resistant Prostate Cancer Patient Summary This clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and whose cancer progressed on or after they were previously treated with a next-generation Hormonal Agent (NHA). This trial is comparing the...
Omaha-003 Patient Summary – Metastatic Castration Resistant
This clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer. Study of Investigational Drug, MK5684, in Participants with Metastatic Castration-Resistant Prostate Cancer Patient Summary The Omaha-003 clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and failed to respond to drugs or surgery to block the testes from making hormones and after treatment with...
I-DXd Patient Summary – Metastatic Castration Resistant
Phase 3 Study of I-DXd Versus Docetaxel in mCRPC (MK-2400-001/IDeate-Prostate01) Testing I-DXd alone versus docetaxel for people with metastatic castration-resistant prostate cancer (mCRPC) About This Study Metastatic castration-resistant prostate cancer is a cancer that has spread and no longer responds to hormone-lowering treatment. There is currently no cure, and more research is needed. Study Purpose Researchers seek to learn how safe I-DXd is and see how well it works compared to docetaxel, which is a standard treatment for mCRPC. About the Investigational Drug (I-DXd, MK-2400) I-DXd...
IDeate/Prostate02 Patient Summary – Metastatic Castration Resistant
MK-2400-01A: Substudy of I-DXd-based Treatment Combinations or as Monotherapy in mCRPC Testing I-DXd alone or in combination with other treatments for people with metastatic castration-resistant prostate cancer (mCRPC). About This Study Metastatic castration-resistant prostate cancer is a cancer that has spread and no longer responds to hormone-lowering treatment. There is currently no cure, and more research is needed. Study Purpose Researchers seek to learn how safe I-DXd is, by itself or with other drugs, identify the best dose, and see how the cancer responds to treatment. About the...
